ArticlePloS one2021

Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

PLOS ONE StaffPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.